4 Benefits of Using Clinion eCOA

During the COVID-19 crisis, CROs and pharmaceutical companies faced numerous challenges. Many clinical trials either slowed down or came to a complete halt as hospitals redirected medical staff to support growing healthcare demands, leaving limited resources for other activities.

Clinion supported several organizations in running their clinical operations during the pandemic, including multiple therapies and Bharat Biotech’s COVAXIN studies. Despite the constraints, our integrated platform helped these companies manage their entire clinical trial process with:

• Minimal interpersonal contact
• High operational efficiency
• Superior data accuracy
  

Our eCOA solution played a critical role in enabling sponsors to continue their studies without interruptions. Below are some key benefits of using Clinion eCOA for clinical trials.

Traditionally, patients are required to visit research sites for regular checkups to assess medication effects, side effects, and overall health parameters. During the pandemic, however, these visits increased patients’ risk of exposure to COVID-19, discouraging participation.

With Clinion eCOA, sponsors captured patient data through a simple, lightweight mobile app, allowing participants to share information securely from home. The app ensures data is collected in a detailed and structured format, maintaining the same level of accuracy as in-person reporting while reducing risk and improving patient safety.

Manual documentation of patient responses was limited to in-person visits, which often occurred less frequently than researchers desired. With eCOA, data can be captured as often as required through scheduled digital entries, allowing researchers to collect richer and more consistent data without requiring patients to travel.

This flexibility enhances patient engagement by empowering participants to contribute actively from the comfort of their homes.

Decentralized clinical trials (DCTs) rely heavily on digital infrastructure, and eCOA plays a vital role in this transformation. In traditional trials, patients often bear the burden of frequent travel to test sites. With eCOA-powered decentralized trials, data can be collected remotely without compromising quality.

This approach not only reduces the logistical burden on patients but also expands access to participants in remote areas, improving recruitment rates and reducing dropout rates, which are essential for the future of clinical research.

Using Clinion eCOA, sponsors can set up automated alerts and reminders for patients. These can include medication schedules, dosage reminders, and site visit notifications. Such alerts encourage better adherence and participation, leading to more accurate and reliable study outcomes.

CROs and pharmaceutical companies today have access to advanced digital tools that can help them overcome disruptions such as the COVID-19 pandemic. By deploying solutions like Clinion eCOA, organizations can ensure continuity, enhance patient safety, and improve overall study outcomes.

To learn more about how Clinion can help you manage your clinical trials with our suite of AI-enabled solutions, contact us at sales@stage-clini.clinion.com.